Psychedelics Deutsche Bank initiates bullish coverage of psychedelics company AtaiBeckley The financial institution has given the drug developer a Buy rating a US$12 share target Rowan DunneMarch 31, 2026
Psychedelics Beckley Psytech & atai Life Sciences to combine expertise in pivotal merger The important news follows the passing of Beckley co-founder Amanda Feilding Rowan DunneJune 2, 2025